Discovery of Novel Isoindolin-1-one Derivatives as GABA

Epilepsy is one of the most common and life-threatening neurological diseases, and the GABAARs are important therapeutic targets for epilepsy. Herein, a series of novel 2,7-disubstituted isoindolin-1-one derivatives were designed and synthesized, and extensive structure-activity relationships led to a number of highly potent PAMs of GABAARs with EC50 values at 10-7-10-8 M level and Emax value of 5-15-fold. In particular, Cpd48 exhibited strong in vitro potentiation effects toward both synaptic and extra-synaptic GABAARs, and produced highly potent in vivo efficacies in mouse seizure models, including sc-PTZ (ED50 = 8.20 mg/kg), MES (ED50 = 2.68 mg/kg), and pilocarpine-induced SE model. Furthermore, Cpd48 displayed a high selectivity for GABAARs over other key CNS ion channels (>100-fold). It also possessed desirable plasma PK properties and BBB penetration ability. Altogether, Cpd48 could serve as a unique lead compound for further developing new antiseizure agents with differentiated pharmacological profiles.